Nucleo Analysis: $4M Raised
What is Nucleo?
AI-powered body composition and tumor analysis
Location
San Francisco, United States
Employees
1-10
Founded
2022
YC Batch
F25
Yc Partner
Nicolas Dessaigne
Product Features & Capabilities
- Body composition analysis
- Tumor lesion sizing
- Target vs non-target lesion classification
Use Cases
Automatic detection of fat and muscle mass in CT scans; Precise measurement of tumor lesions; Automated classification of lesions according to RECIST criteria; Streamlining clinical workflows in oncology; Supporting healthcare providers with rapid analysis
How much Nucleo raised
Funding - $4M
Who are the founders of Nucleo
LP
Luca Pegolotti
Co-founder & CTO
RB
Robert Brown
Chief Executive Officer
AI
Angelica Iacovelli
CEO, Co-founder
LM
Lucy Maguire
CEO and Programme Director
Other Considerations
Backed by Y Combinator; Collaborates with top hospitals in the US and worldwide; Achieves high agreement rates with expert radiologists
See something that needs updating? Suggest edits to this profile.